Table 2 Characteristics of CSRV by screening period in patients with positive PCR.
P1 | P2 | P3 | P-value | |
|---|---|---|---|---|
PCR+ episodes, n (%) | 115 (38.3) | 145 (48.3) | 40 (13.3) | P < 0.001 |
Median days from allo-HSCT to CSRV (range) | 260 (−8 to 4766) | 275 (−7 to 3993) | 473 (−4 to 5422) | P = 0.015 |
Flu vaccination, n (%) | 24 (20.9) | 66 (45.5) | 21 (52.5) | P < 0.001 |
IgG mg/dL, median (range) | 577 (109–1350) | 662 (0–14100) | 702 (220–1716) | ns |
Immunoglobulin support, n (%) | 15 (13) | 19 (13.1) | 7 (17.5) | ns |
HLA mismatched donor/recipient, n (%) | 45 (39.1) | 51 (35.2) | 12 (30) | ns |
Age ≥ 40, n (%) | 71 (61.7) | 115 (79.3) | 31 (77.5) | P = 0.005 |
MAC regimen, n (%) | 72 (62.6) | 70 (48.3) | 23 (57.5) | ns |
ALC < 0.5 × 10e9/mL, n (%) | 27 (23.5) | 28 (19.3) | 6 (15) | ns |
ANC < 0.5 × 10e9/mL, n (%) | 5 (4.3) | 9 (6.2) | 0 (0) | ns |
Active GvHD, n (%) | 57 (49.6) | 65 (44.8) | 15 (37.5) | ns |
Under IST, n (%) | 75 (65.2) | 95 (65.5) | 22 (55) | ns |
Corticosteroids, n (%) | 30 (26.1) | 32 (22.1) | 6 (15) | ns |
ISI (Low-moderate-high risk), n (%) | 48–57–10 (41.7–49.6–8.7) | 51–84–8 (35.2–57.9–5.5) | 13–23–0 (35–62.5–0) | ns |
Antibiotic therapy, n (%) | 82 (71.4) | 105 (72.4) | 30 (75) | ns |
Fever (>37.8 °C), n (%) | 47 (40.9) | 62 (42.8) | 20 (50) | ns |
URTD, n (%) | 111 (96.5) | 142 (97.9) | 33 (82.5) | P < 0.001 |
LRTD, n (%) | 55 (47.8) | 39 (26.9) | 15 (37.5) | P = 0.002 |
CSRV co-infection, n (%) | 25 (21.7) | 24 (16.6) | 2 (5) | P = 0.051 |
Hospitalization, n (%) | 39 (34) | 34 (23.4) | 10 (25) | |
Day-90 all-cause mortality, n (%) | 2 (1.8) | 2 (1.4) | 5 (12.5) | P = 0.001 |
Median follow-up after CSRV, days (range) | 720 (14–950) | 426 (7–580) | 138 (5–224) | P < 0.001 |
